Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment

NEW YORK (GenomeWeb) – Proteomics International Laboratories announced today that it has signed an agreement to evaluate its PromarkerD test in clinical trials of Dimerix's investigational chronic kidney disease drug DMX-200.

PromarkerD uses a panel of blood-based protein biomarkers to both predict risk of developing kidney disease in diabetics and diagnose patients with diabetic kidney disease. DMX-200 is a combination of the anti-inflammatory agent propagermanium and the angiotensin II type I receptor blocker irbesartan, and was recently shown to be safe — with potential signs of efficacy — in a Phase IIa study.

Under the terms of the deal, the companies will use PromarkerD to monitor the response of healthy volunteers to DMX-200 in an Phase I study currently underway in Australia, as well as in upcoming Phase II trials. Dimerix has also been given an option to license PromarkerD for further use if the test is found to be an effective companion diagnostic for DMX-200. Preliminary data from the collaboration are expected next year.

Additional terms were not disclosed.

"Many [chronic kidney disease] patients are diagnosed too late and the existing treatments can have little to no effect," Dimerix CEO Kathy Harrison said in a statement. "Having a test which can predict disease progression will undoubtedly be beneficial to both controlling disease and treating it with new drugs like DMX-200."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.